- Interferon alfa-2b
drugbox
IUPAC_name = N/A
width =
CAS_number =
ATC_prefix = L03
ATC_suffix = AB05
ATC_supplemental =
PubChem =
DrugBank =
chemical_formula =
molecular_weight =
bioavailability =
protein_bound =
metabolism =
elimination_half-life =
pregnancy_US = C
pregnancy_category =
legal_UK = POM
legal_US = Rx-only
legal_status =
routes_of_administration = Subcutaneous, intramuscularInterferon alfa-2b is an
antiviral drug originally discovered in the laboratory of Charles Weissmann at the University of Zurich, developed at Biogen, and ultimately marketed by Schering-Plough under the tradename Intron-A. It has been used for a wide range of indications, including viral infections and cancers.This drug is approved around the world for the treatment of chronic
hepatitis C , chronichepatitis B , hairy cell leukemia, chronic myelogenous leukemia, multiple myeloma, follicular lymphoma, carcinoid tumor, and malignant melanoma.ee also
*
Interferon External links
* [http://www.introna.com/ Product website]
* [http://www.emea.europa.eu/humandocs/PDFs/EPAR/Introna/H-281-PI-en.pdf Intron-A Summary of Product Characteristics]
* [http://www.ncbi.nlm.nih.gov/pubmed/6987533?ordinalpos=7&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_DefaultReportPanel.Pubmed_RVDocSum First publication in Nature of recombinant interferon]
Wikimedia Foundation. 2010.